Abpro Holdings (ABPO) Net Income (2022 - 2026)
Abpro Holdings' (ABPO) quarterly Net Income came in at -$983000.0 in Q1 2026, up 73.27% YoY from -$567335.0 in Q1 2025, and up 49.46% on a QoQ basis from -$1.9 million in Q4 2025.
Abpro Holdings (ABPO) Net Income (2022 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 5 years of Net Income data on file, last reported at -$983000.0 in Q1 2026.
- Quarterly Net Income rose 73.27% year-over-year to -$983000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.9 million (up 6.77% YoY) and the FY2025 annual result came in at -$42.1 million, up 2.49% from the prior year.
- Net Income grew to -$983000.0 in Q1 2026, from -$1.9 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $2.1 million in Q1 2023 to a low of -$3.7 million in Q1 2025.
- A 5-year average of -$684899.9 and a median of -$338851.0 in 2024 frame the typical range for Net Income.
- Annual changes were most pronounced in 2023 — Net Income surged 507.68% — and 2024, when it tumbled 42029.25%.
- Tracing ABPO's Net Income over 5 years: stood at $1.5 million in 2022, then tumbled by 100.5% to -$7242.0 in 2023, then plunged by 42029.25% to -$3.1 million in 2024, then jumped by 36.25% to -$1.9 million in 2025, then soared by 49.46% to -$983000.0 in 2026.
- The last three Net Income figures came in at -$983000.0 (Q1 2026), -$1.9 million (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | -1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -983,000.00 |
| Dec 31, 2025 | -1.95 Mn |
| Sep 30, 2025 | -1.54 Mn |
| Jun 30, 2025 | -2.43 Mn |
| Mar 31, 2025 | -3.68 Mn |
| Dec 31, 2024 | -3.05 Mn |
| Sep 30, 2024 | -335,100.00 |
| Jun 30, 2024 | -338,851.00 |
| Mar 31, 2024 | -1.05 Mn |
| Dec 31, 2023 | -7,242.00 |
| Sep 30, 2023 | -44,630.00 |
| Jun 30, 2023 | 802,803.00 |
| Mar 31, 2023 | 2.07 Mn |
| Dec 31, 2022 | 1.46 Mn |
| Sep 30, 2022 | 652,421.00 |
| Jun 30, 2022 | -196,919.00 |
| Mar 31, 2022 | -1.03 Mn |